| P2093 | author name string | Kailash Prasad | |
| P2860 | cites work | Regulation of complement activation by C-reactive protein | Q22010264 |
| | C-Reactive Protein, Antiinflammatory Drugs, and Quality of Life in Diabetes | Q28165737 |
| | Role of C-reactive protein in cardiovascular disease | Q28166927 |
| | Effect of angiotensin-converting enzyme inhibitors, beta blockers, statins, and aspirin on C-reactive protein levels in outpatients with heart failure | Q28167773 |
| | Rofecoxib, a COX-2 inhibitor, lowers C-reactive protein and interleukin-6 levels in patients with acute coronary syndromes | Q28168585 |
| | Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs | Q28184413 |
| | Effects of low-dose aspirin on serum C-reactive protein and thromboxane B2 concentrations: a placebo-controlled study using a highly sensitive C-reactive protein assay | Q28185558 |
| | Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study | Q28186001 |
| | Beta-blockers are associated with lower C-reactive protein concentrations in patients with coronary artery disease | Q28192531 |
| | Selective COX-2 inhibition improves endothelial function in coronary artery disease | Q28194726 |
| | Relationship between effects of statins, aspirin and angiotensin II modulators on high-sensitive C-reactive protein levels | Q28196720 |
| | A randomized comparison of the effects of aspirin and clopidogrel on thrombotic risk factors and C-reactive protein following myocardial infarction: the CADET trial | Q28210362 |
| | Acute-phase proteins and other systemic responses to inflammation | Q28296941 |
| | C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women | Q29616306 |
| | Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men | Q29619308 |
| | Intensive versus moderate lipid lowering with statins after acute coronary syndromes | Q29619716 |
| | C-reactive protein and ischemia in users and nonusers of beta-blockers and statins: data from the Heart and Soul Study | Q30763122 |
| | C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis | Q30982893 |
| | Tamoxifen and cardiac risk factors in healthy women: Suggestion of an anti-inflammatory effect | Q31825733 |
| | Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia | Q32129328 |
| | C-reactive protein as a cardiovascular risk factor: more than an epiphenomenon? | Q33678964 |
| | C-reactive protein, inflammation, and coronary risk | Q33843636 |
| | Comparative effects of valsartan versus amlodipine on left ventricular mass and reactive oxygen species formation by monocytes in hypertensive patients with left ventricular hypertrophy | Q44917506 |
| | Comparative effects of AT1-antagonism and angiotensin-converting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery disease | Q44984910 |
| | Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation | Q45020438 |
| | Non-HDL cholesterol level is reliable to be an early predictor for vascular inflammation in type 2 diabetes mellitus. | Q45050695 |
| | C-reactive protein increases oxygen radical generation by neutrophils | Q45065931 |
| | Effects of celecoxib on high-sensitivity C-reactive protein in chronic peritoneal dialysis patients | Q45088496 |
| | Association between diet, lifestyle, metabolic cardiovascular risk factors, and plasma C-reactive protein levels | Q45146140 |
| | The effect of fenofibrate on the levels of high sensitivity C-reactive protein in dyslipidemic obese patients | Q45156479 |
| | Effect of antispastic agents (calcium antagonists and/or isosorbide dinitrate) on high-sensitivity C-reactive protein in patients with coronary vasospastic angina pectoris and no hemodynamically significant coronary artery disease | Q45201799 |
| | C-reactive protein levels and outcomes after statin therapy | Q45213511 |
| | Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease | Q45213515 |
| | Aggressive antihypertensive therapy based on hydrochlorothiazide, candesartan or lisinopril as initial choice in hypertensive type II diabetic individuals: effects on albumin excretion, endothelial function and inflammation in a double-blind, random | Q45222030 |
| | C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis. | Q46005836 |
| | Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study | Q46146631 |
| | Hypocholesterolemic and antiatherosclerotic effect of flax lignan complex isolated from flaxseed | Q46389956 |
| | Carvedilol reduces plasma 8-hydroxy-2'-deoxyguanosine in mild to moderate hypertension: a pilot study | Q46443729 |
| | The effect of the phytoestrogen genistein and hormone replacement therapy on homocysteine and C-reactive protein level in postmenopausal women | Q46447018 |
| | The effect of fenofibrate on the levels of high sensitivity C-reactive protein in dyslipidaemic hypertensive patients | Q46457314 |
| | Influence of the angiotensin converting enzyme inhibitor ramipril on high-sensitivity C-reactive protein (hs-CRP) in patients with documented atherosclerosis | Q46469664 |
| | Comparison of the effects of ramipril versus telmisartan in reducing serum levels of high-sensitivity C-reactive protein and oxidized low-density lipoprotein cholesterol in patients with type 2 diabetes mellitus | Q46498945 |
| | Combined effects of losartan and pravastatin on interstitial inflammation and fibrosis in chronic cyclosporine-induced nephropathy. | Q46531547 |
| | Effects of raloxifene, hormone therapy, and soy isoflavone on serum high-sensitive C-reactive protein in postmenopausal women | Q46560125 |
| | Atorvastatin lowers plasma low-density lipoprotein cholesterol and C-reactive protein in Japanese type 2 diabetic patients | Q46833325 |
| | Vitamin E modulation of C-reactive protein in smokers with acute coronary syndromes | Q47835775 |
| | Possible contribution of C-reactive protein within coronary plaque to increasing its own plasma levels across coronary circulation | Q48010616 |
| | Effect of oxygen free radicals on cardiovascular function at organ and cellular levels. | Q54352247 |
| | Reduction of Serum Cholesterol and Hypercholesterolemic Atherosclerosis in Rabbits by Secoisolariciresinol Diglucoside Isolated From Flaxseed | Q56483725 |
| | Preprocedural serum levels of C-reactive protein predict early complications and late restenosis after coronary angioplasty | Q58230324 |
| | Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels | Q33942737 |
| | Vascular inflammation and the renin-angiotensin system | Q33960784 |
| | Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women | Q34067367 |
| | Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus | Q34142970 |
| | Effects of transdermal estrogen replacement therapy on cardiovascular risk factors | Q34482114 |
| | Niacin extended-release/lovastatin: combination therapy for lipid disorders | Q35020544 |
| | Clinical application of C-reactive protein for cardiovascular disease detection and prevention | Q35054464 |
| | Priapism caused by infection and an inflammatory process in the pelvic region | Q35093187 |
| | Irbesartan significantly reduces C reactive protein concentrations after 1 month of treatment in unstable angina | Q35584163 |
| | Antioxidants in the prevention of human atherosclerosis. Summary of the proceedings of a National Heart, Lung, and Blood Institute Workshop: September 5-6, 1991, Bethesda, Maryland | Q36140573 |
| | The liver as the site of C-reactive protein formation | Q36267987 |
| | Effects of hormone therapy on C-reactive protein and IL-6 in postmenopausal women: a review article | Q36359547 |
| | Effects of simvastatin on C-reactive protein in mixed hyperlipidemic and hypertriglyceridemic patients | Q38454661 |
| | Angiotensin-Converting Enzyme Inhibitor Use Is Associated With Reduced Plasma Concentration of C-Reactive Protein in Patients With First-Ever Ischemic Stroke | Q40551007 |
| | C-reactive protein and outcome after ischemic stroke | Q40814776 |
| | C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study | Q40828366 |
| | C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction | Q40857092 |
| | Determination of C-reactive protein in the blood as a measure of the activity of the disease process in acute rheumatic fever | Q41067155 |
| | Induction of inflammatory cytokine release from cultured human monocytes by C-reactive protein | Q41098875 |
| | Results of therapy with carvedilol, a beta-blocker vasodilator with antioxidant properties, in hypertensive patients | Q41721179 |
| | Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease | Q43614603 |
| | Influence of pravastatin on lipoproteins, and on endothelial, platelet, and inflammatory markers in subjects with peripheral artery disease | Q43651437 |
| | Role of angiotensin II type 1 receptor in the regulation of cellular adhesion molecules in atherosclerosis | Q43692085 |
| | Both fenofibrate and atorvastatin improve vascular reactivity in combined hyperlipidaemia (fenofibrate versus atorvastatin trial--FAT). | Q43782722 |
| | Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Study | Q43788768 |
| | Fosinopril versus amlodipine comparative treatments study: a randomized trial to assess effects on plasminogen activator inhibitor-1. | Q43869290 |
| | Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia | Q43919588 |
| | Short-term effects of atorvastatin on C-reactive protein | Q43992481 |
| | Simvastatin lowers C-reactive protein within 14 days: an effect independent of low-density lipoprotein cholesterol reduction | Q44138516 |
| | The impact of plasma levels of C-reactive protein, lipoprotein (a) and homocysteine on the long-term prognosis after successful coronary stenting: The Global Evaluation of New Events and Restenosis After Stent Implantation Study | Q44188976 |
| | Modulation of the inflammatory response to cardiopulmonary bypass by dopexamine and epidural anesthesia | Q44208725 |
| | Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia | Q44210740 |
| | Strong decrease of high sensitivity C-reactive protein with high-dose atorvastatin in patients with type 2 diabetes mellitus | Q44249465 |
| | Plasma fibronectin level and its relationships with lipids, lipoproteins and C-reactive protein in patients with dyslipidaemia during lipid-lowering therapy | Q44287384 |
| | Early use of beta-blockers is associated with attenuation of serum C-reactive protein elevation and favorable short-term prognosis after acute myocardial infarction | Q44317194 |
| | Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial | Q44420382 |
| | Double blind, randomized study of estradiol replacement therapy on markers of inflammation, coagulation and fibrinolysis | Q44430821 |
| | Timing of antioxidant vitamin ingestion alters postprandial proatherogenic serum markers | Q44488018 |
| | Effects of a dietary portfolio of cholesterol-lowering foods vs lovastatin on serum lipids and C-reactive protein | Q44522412 |
| | Alpha and gamma tocopherol metabolism in healthy subjects and patients with end-stage renal disease | Q44545033 |
| | Effects of atorvastatin on glucose homeostasis, postprandial triglyceride response and C-reactive protein in subjects with impaired fasting glucose | Q44553382 |
| | Pleiotropic effects of angiotensin II receptor blocker in hypertensive patients | Q44574645 |
| | Angiotensin II receptor blocker valsartan suppresses reactive oxygen species generation in leukocytes, nuclear factor-kappa B, in mononuclear cells of normal subjects: evidence of an antiinflammatory action | Q44582536 |
| | Candesartan Reduces Oxidative Stress and Inflammation in Patients with Essential Hypertension | Q44657547 |
| | High-intensity statin treatment for coronary heart disease | Q44783943 |
| | Intensive statin therapy--a sea change in cardiovascular prevention | Q44790689 |
| | Effects of carvedilol on oxidative stress in polymorphonuclear and mononuclear cells in patients with essential hypertension | Q44816345 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 33-50 | |
| P577 | publication date | 2006-01-01 | |
| P1433 | published in | Cardiovascular Drug Reviews | Q13455172 |
| P1476 | title | C-reactive protein (CRP)-lowering agents | |
| P478 | volume | 24 | |